☰

Lawrence P. Carter, Ph.D. - Publications

Affiliations: 
Jazz Pharmaceuticals, Palo Alto, CA, United States 
Area:
Human behavioral pharmacology
Tree Info Grants Similar researchers PubMed Report error

41 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Zomorodi K, Chen D, Lee L, Swearingen D, Carter LP. A Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants. Clinical Pharmacology in Drug Development. PMID 32935460 DOI: 10.1002/Cpdd.867  0.418
2020 Strollo PJ, Malhotra A, Strohl K, Pepin J, Schweitzer P, Lammers G, Hedner J, Baladi M, Carter L, Bujanover S, Menno D, Dauvilliers Y. 0772 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Narcolepsy Sleep. 43: A293-A293. DOI: 10.1093/Sleep/Zsaa056.768  0.368
2020 Strollo PJ, Malhotra A, Strohl K, Pepin J, Schweitzer P, Lammers G, Hedner J, Baladi M, Carter L, Bujanover S, Menno D, Dauvilliers Y. 0693 Effects Of Solriamfetol On 24-hour Blood Pressure Patterns In Participants With Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Sleep. 43: A264-A264. DOI: 10.1093/Sleep/Zsaa056.689  0.365
2019 Schweitzer PK, Mayer G, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Black J, Malhotra A, Strohl KP. P004 Solriamfetol for excessive daytime sleepiness in obstructive sleep apnoea: a randomised controlled trial Bmj Open Respiratory Research. 6. DOI: 10.1136/Bmjresp-2019-Bssconf.4  0.343
2019 Black J, Dauvilliers Y, Plazzi G, Shapiro CM, Mayer G, Corser BC, Emsellem HA, Chen D, Carter LP, Wang H, Thorpy MJ. P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2 Bmj Open Respiratory Research. 6. DOI: 10.1136/Bmjresp-2019-Bssconf.3  0.354
2019 Malhotra A, Strohl KP, Carter LP, Baladi M, Lee L, Bujanover S, Thorpy MJ. 0618 Weight Change Associated with Solriamfetol Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy or Obstructive Sleep Apnea Sleep. 42: A246-A246. DOI: 10.1093/Sleep/Zsz067.616  0.649
2019 Strollo PJ, Schwab R, Hedner J, Collop N, Chen D, Carter LP, Bujanover S, Menno D, Black J, Pepin J, Redline S. 0570 Dose Titration Of Solriamfetol In Participants With Obstructive Sleep Apnea From A 6-week Randomized-withdrawal Trial Sleep. 42: A227-A227. DOI: 10.1093/Sleep/Zsz067.568  0.332
2019 Lammers G, Bogan R, Schweitzer P, Menno D, Carter L, Bron M, Bujanover S, Baladi M, Scheckner B, Mayer G. Thresholds for clinically meaningful changes on the epworth sleepiness scale and maintenance of wakefulness test sleep latency Sleep Medicine. 64: S210. DOI: 10.1016/J.Sleep.2019.11.587  0.65
2018 Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, Sellers E. A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor. Journal of Psychopharmacology (Oxford, England). 269881118796814. PMID 30269642 DOI: 10.1177/0269881118796814  0.509
2018 Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky AJ. Characterization of the neurochemical and behavioral effects of solriamfetol (JZP-110), a selective dopamine and norepinephrine reuptake inhibitor. The Journal of Pharmacology and Experimental Therapeutics. PMID 29891587 DOI: 10.1124/Jpet.118.248120  0.68
2017 Carter LP, Sellers E, Henningfield J, Wang G, Lu Y, Kelsh D, Vince B. Evaluation of human abuse liability of JZP-110 Drug and Alcohol Dependence. 171: e36. DOI: 10.1016/J.Drugalcdep.2016.08.112  0.496
2017 Baladi M, Carter LP, Black J, Bergman J. Evaluation of the effects of jzp-110 in nonclinical models of abuse liability Drug and Alcohol Dependence. 171: e14. DOI: 10.1016/J.Drugalcdep.2016.08.054  0.673
2015 Reissig CJ, Harrison JA, Carter LP, Griffiths RR. Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. Psychopharmacology. 232: 871-83. PMID 25199955 DOI: 10.1007/S00213-014-3721-0  0.79
2014 Sheffer CE, Christensen DR, Landes R, Carter LP, Jackson L, Bickel WK. Delay discounting rates: a strong prognostic indicator of smoking relapse. Addictive Behaviors. 39: 1682-9. PMID 24878037 DOI: 10.1016/J.Addbeh.2014.04.019  0.339
2013 Carter LP, Kleykamp BA, Griffiths RR, Mintzer MZ. Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers. Psychopharmacology. 226: 53-63. PMID 23096769 DOI: 10.1007/S00213-012-2883-X  0.771
2013 Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug and Alcohol Dependence. 128: 206-13. PMID 22989498 DOI: 10.1016/J.Drugalcdep.2012.08.025  0.773
2013 Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ. Corrigendum to Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans [Drug Alcohol Depend. 128 (2013) 206-213] Drug and Alcohol Dependence. 133: 294. DOI: 10.1016/J.Drugalcdep.2013.06.006  0.741
2013 Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. Erratum to: High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens Psychopharmacology. 228: 513-513. DOI: 10.1007/S00213-013-3172-Z  0.764
2012 Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology. 223: 1-15. PMID 22526529 DOI: 10.1007/S00213-012-2680-6  0.776
2012 Sheffer C, Mackillop J, McGeary J, Landes R, Carter L, Yi R, Jones B, Christensen D, Stitzer M, Jackson L, Bickel W. Delay discounting, locus of control, and cognitive impulsiveness independently predict tobacco dependence treatment outcomes in a highly dependent, lower socioeconomic group of smokers. The American Journal On Addictions / American Academy of Psychiatrists in Alcoholism and Addictions. 21: 221-32. PMID 22494224 DOI: 10.1111/J.1521-0391.2012.00224.X  0.465
2011 Carter LP. Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault. Drug Testing and Analysis. 3: 586-93. PMID 21960542 DOI: 10.1002/Dta.203  0.374
2009 Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Abuse liability assessment of tobacco products including potential reduced exposure products. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 3241-62. PMID 19959676 DOI: 10.1158/1055-9965.Epi-09-0948  0.525
2009 McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, Wissel J, Waxman D, Carter LP, Seeger V, Johnson RE. Case histories in pharmaceutical risk management. Drug and Alcohol Dependence. 105: S42-55. PMID 19767156 DOI: 10.1016/J.Drugalcdep.2009.08.003  0.433
2009 Carter LP, Griffiths RR, Mintzer MZ. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology. 206: 141-54. PMID 19543883 DOI: 10.1007/S00213-009-1589-1  0.803
2009 Carter LP, Pardi D, Gorsline J, Griffiths RR. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug and Alcohol Dependence. 104: 1-10. PMID 19493637 DOI: 10.1016/J.Drugalcdep.2009.04.012  0.617
2009 Carter LP, Griffiths RR. Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug and Alcohol Dependence. 105: S14-25. PMID 19443137 DOI: 10.1016/J.Drugalcdep.2009.04.003  0.633
2009 Carter LP, Koek W, France CP. Behavioral analyses of GHB: receptor mechanisms. Pharmacology & Therapeutics. 121: 100-14. PMID 19010351 DOI: 10.1016/J.Pharmthera.2008.10.003  0.499
2009 Carter LP, Mintzer MZ, Griffiths RR. Amnestic effects of sodium oxybate are less than those of triazolam-reply to Drs. Zvosec and Smith Psychopharmacology. 207: 511-512. DOI: 10.1007/S00213-009-1664-7  0.773
2007 Carter LP, Griffiths RR, Suess PE, Casada JH, Wallace CL, Roache JD. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects. The Journal of Pharmacology and Experimental Therapeutics. 322: 749-59. PMID 17502431 DOI: 10.1124/Jpet.107.119693  0.71
2006 Carter LP, Koek W, France CP. Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats. The European Journal of Neuroscience. 24: 2595-600. PMID 17100847 DOI: 10.1111/J.1460-9568.2006.05146.X  0.487
2006 Carter LP, Richards BD, Mintzer MZ, Griffiths RR. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 2537-51. PMID 16880774 DOI: 10.1038/Sj.Npp.1301146  0.818
2006 Carter LP, Chen W, Coop A, Koek W, France CP. Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348. European Journal of Pharmacology. 538: 85-93. PMID 16647701 DOI: 10.1016/J.Ejphar.2006.03.039  0.52
2006 Koek W, Carter LP, Wu H, Coop A, France CP. Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone. Behavioural Pharmacology. 17: 239-47. PMID 16572002 DOI: 10.1097/00008877-200605000-00005  0.512
2005 Koek W, Carter LP, Lamb RJ, Chen W, Wu H, Coop A, France CP. Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam. The Journal of Pharmacology and Experimental Therapeutics. 314: 170-9. PMID 15774716 DOI: 10.1124/Jpet.105.083394  0.599
2005 Carter LP, Wu H, Chen W, Matthews MM, Mehta AK, Hernandez RJ, Thomson JA, Ticku MK, Coop A, Koek W, France CP. Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all, of the behavioral effects of GHB and GABAB receptor agonists. The Journal of Pharmacology and Experimental Therapeutics. 313: 1314-23. PMID 15769868 DOI: 10.1124/jpet.104.077578  0.475
2005 Carter LP, Chen W, Wu H, Mehta AK, Hernandez RJ, Ticku MK, Coop A, Koek W, France CP. Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug and Alcohol Dependence. 78: 91-9. PMID 15769562 DOI: 10.1016/J.Drugalcdep.2004.10.002  0.58
2004 Carter LP, Unzeitig AW, Wu H, Chen W, Coop A, Koek W, France CP. The Discriminative stimulus effects of gamma-hydroxybutyrate and related compounds in rats discriminating baclofen or diazepam: The role of GABA(B) and GABA(A) receptors. The Journal of Pharmacology and Experimental Therapeutics. 309: 540-7. PMID 14742739 DOI: 10.1124/jpet.103.062950  0.484
2004 Koek W, Flores LR, Carter LP, Lamb RJ, Chen W, Wu H, Coop A, France CP. Discriminative stimulus effects of gamma-hydroxybutyrate in pigeons: role of diazepam-sensitive and -insensitive GABA(A) and GABA(B) receptors. The Journal of Pharmacology and Experimental Therapeutics. 308: 904-11. PMID 14718595 DOI: 10.1124/Jpet.103.056093  0.606
2004 Carter LP, Wu H, Chen W, Cruz CM, Lamb RJ, Koek W, Coop A, France CP. Effects of gamma-hydroxybutyrate (GHB) on schedule-controlled responding in rats: role of GHB and GABAB receptors. The Journal of Pharmacology and Experimental Therapeutics. 308: 182-8. PMID 14569056 DOI: 10.1124/Jpet.103.058909  0.648
2003 Carter LP, Flores LR, Wu H, Chen W, Unzeitig AW, Coop A, France CP. The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies. The Journal of Pharmacology and Experimental Therapeutics. 305: 668-74. PMID 12606639 DOI: 10.1124/jpet.102.047860  0.544
2003 Wu H, Zink N, Carter LP, Mehta AK, Hernandez RJ, Ticku MK, Lamb R, France CP, Coop A. A tertiary alcohol analog of gamma-hydroxybutyric acid as a specific gamma-hydroxybutyric acid receptor ligand. The Journal of Pharmacology and Experimental Therapeutics. 305: 675-9. PMID 12606613 DOI: 10.1124/Jpet.102.046797  0.594
Show low-probability matches.